Neurocrine Biosciences
NBIX
#1366
Rank
S$20.10 B
Marketcap
S$201.61
Share price
0.84%
Change (1 day)
19.14%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.59. In 2024 the company made an earnings per share (EPS) of S$4.38 an increase over its 2023 EPS that were of S$3.29.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6128.14%
2024S$4.3833.07%
2023S$3.2957.76%
2022S$2.0969.47%
2021S$1.23-78.21%
2020S$5.65990%
2019S$0.5281.82%
2018S$0.29-113.5%
2017S-$2.110.62%
2016S-$2.1057.28%
2015S-$1.3425.61%
2014S-$1.0618.84%
2013S-$0.89-1085.71%
2012S$0.09075

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
S$0.03889-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.29-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
S-$79.08-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$26.60 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$1.75-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$2.23-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.22-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.63-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA